GlassScriptPhysician profile
Tara I Ezzell
NPI 1750399051
$8,302.55
in general payments reported to CMS, 2019-2025
41 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $442 · 2021: $767 · 2022: $1,564 · 2023: $1,152 · 2024: $1,184 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.32 |
| Education | $276.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.15 | 2019-2025 | |
| Janssen Biotech, INC. | $1,191.78 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $692.04 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $577.77 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $452.22 | 2019-2025 | |
| Lilly USA, LLC | $451.35 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $326.88 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $323.92 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $304.68 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $276.38 | 2020-2025 | |
| Almirall LLC | $261.35 | 2019-2022 | |
| Pfizer INC. | $256.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $223.92 | 2023-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $184.99 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.47 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $157.40 | 2019-2025 | Bimzelx |
| Amgen INC. | $138.13 | 2023-2025 | Otezla, Otezla |
| Sebela Pharmaceuticals INC. | $128.67 | 2019 | |
| Janssen Scientific Affairs, LLC | $112.61 | 2022 | |
| Arcutis Biotherapeutics, INC. | $95.68 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.02 | 2022-2025 | Spevigo |
| Smith+Nephew, INC. | $84.90 | 2020-2023 | Collagenase Santyl |
| Genentech USA, INC. | $69.34 | 2019-2023 | Erivedge |
| Kerecis Limited | $64.28 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Celgene Corporation | $62.46 | 2019 | |
| Allergan, INC. | $42.55 | 2019-2022 | |
| Elekta, INC. | $41.59 | 2025 | Flexitron Hdr |
| Biofrontera INC. | $32.51 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $29.99 | 2025 | |
| Dermavant Sciences, INC. | $25.53 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $24.72 | 2024 | Ycanth |
| Journey Medical Corporation | $23.03 | 2022 | |
| Dusa Pharmaceuticals, INC. | $22.71 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.53 | 2020 | |
| Organogenesis INC. | $20.10 | 2021 | |
| Lnhc, INC | $19.12 | 2025 | Zelsuvmi |
| Sandoz INC. | $18.24 | 2019 | |
| Botanix Sb INC | $16.92 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $13.29 | 2020 | |
| Bioventus LLC | $12.77 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Ezzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.